Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology: Scientific and Clinical Aspects of Anemia in CancerMohammad Resa Nowrousian Anemia is a frequent complication of cancer and its treatment. It produces many symptoms and significantly impairs metabolic and physiologic functions as well as patients' activity, well-being and quality of life. Life expectancy is also affected. This book, now being published in its second edition, comprehensively presents the current knowledge on anemia in cancer and its treatment with rhEPO. Future developments are also discussed. Based on updated and new chapters, including a broader spectrum of topics, outstanding international experts describe the scientific and clinical aspects of anemia in various fields of oncology and give diagnostic and therapeutic recommendations on when and how to use rhEPO. The book, considered as a standard work, will again serve as an essential source of information for radiotherapists, medical oncologists, hematologists, internists, pediatricians, surgeons, specialists in transfusion and laboratory medicine, and pharmacologists. |
Contents
| 1 | |
Chapter 2 Biology of EPO and EPOreceptor
| 67 |
Chapter 3 The role of erythropoietin receptor expression on tumor cells
| 81 |
Chapter 4 Problems associated with erythropoietin receptor determination on tumor cells
| 103 |
Chapter 5 Definition classification and characterization of anemia in cancer
| 116 |
Chapter 6 Pathophysiology of anemia in cancer
| 149 |
Chapter 7 Prevalence and incidence of anemia and risk factors for anemia in patients with cancer
| 189 |
Chapter 8 Significance of anemia in cancer chemotherapy
| 207 |
Chapter 20 Recombinant human erythropoietin rhEPO therapy in myelodysplasia | 531 |
Chapter 21 Prediction of response to rhEPO in the anemia of cancer
| 540 |
Chapter 22 rhEPO in hematopoietic stem cell transplantation
| 583 |
Chapter 23 Treatment of anemia with rhEPO in radiation oncology
| 615 |
Chapter 24 Recombinant human erythropoietin in pediatric oncology
| 635 |
Chapter 25 rhEPO in surgical oncology
| 663 |
Chapter 26 Erythropoiesis iron metabolism and iron supplementation during erythropoietin therapy
| 678 |
Chapter 27 Are there risks for use of iron in cancer patients?
| 703 |
Chapter 9 Incidence and impact of anemia in radiation oncology
| 249 |
Chapter 10 Relationship between hemoglobin levels and tumor oxygenation
| 265 |
Chapter 11 Tumor hypoxia and therapeutic resistance
| 283 |
Chapter 12 Symptoms of anemia
| 306 |
Chapter 13 Impact of anemia and red blood cell transfusion on organ function
| 317 |
Chapter 14 Relationship of hemoglobin fatigue and quality of life in anemic cancer patients
| 368 |
Chapter 15 When to use red blood cell transfusions in cancer patients with solid tumours?
| 393 |
Chapter 16 Pharmacology pharmacokinetics and safety of recombinant human erythropoietin preparations
| 406 |
Chapter 17 Epoetin treatment of anemia associated with multiple myeloma and nonHodgkins lymphoma
| 433 |
Chapter 18 rhEPO in anemic patients with solid tumors and chemotherapy efficacy and safety
| 449 |
Chapter 19 Early intervention with recombinant human erythropoietin for chemotherapyinduced anemia
| 509 |
Chapter 28 Metabolic and physiologic effects of rhEPO in anemic cancer patients
| 712 |
Chapter 29 Effects of rhEPO on quality of life in anemic cancer patients
| 729 |
Chapter 30 Thrombosis during therapy with erythropoiesis stimulating agents in cancer
| 745 |
Chapter 31 The effect of rhEPO on survival in anemic cancer patients
| 758 |
Neuroprotective effects of erythropoietin
| 771 |
Chapter 33 rhEPO in patients with anemia and congestive heart failure
| 793 |
Chapter 34 Costeffectiveness of treating cancer anaemia
| 813 |
Addendum 1 | 851 |
| 853 | |
Other editions - View all
Common terms and phrases
activation addition analysis anemia anemic associated baseline blood bone marrow cancer patients carcinoma cause cells changes chemotherapy chronic Clin Oncol clinical compared concentration cost decreased deficiency differentiation disease dose drugs early effect epoetin alfa erythro erythroid et al evaluated expression factor failure fatigue function gene growth Haematol Hb levels head and neck hemoglobin higher hypoxia impact important improve increased indicate induced involved iron malignancies mean measured mechanisms normal observed Oncol Oncology outcome oxygen patients receiving phase predictive present production progenitors prognostic protein radiation radiotherapy randomized recent receptor recombinant human erythropoietin reduced renal reported response rhEPO risk role serum severe showed shown signaling significant significantly solid stage suggest Suppl Table therapy tion tissue transfusion transplantation treated treatment trial tumor values Vaupel weeks